{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:40:26Z","timestamp":1793176826238,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2022YQ010"],"award-info":[{"award-number":["2022YQ010"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972391"],"award-info":[{"award-number":["81972391"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172871"],"award-info":[{"award-number":["82172871"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272950"],"award-info":[{"award-number":["82272950"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["20Y11904800"],"award-info":[{"award-number":["20Y11904800"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22140903700"],"award-info":[{"award-number":["22140903700"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007054","name":"Second Military Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clgc.2023.10.014","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T20:08:33Z","timestamp":1698955713000},"page":"201-209.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patients With Muscle-Invasive Bladder Cancer With Lymphovascular Invasion in Transurethral Resection Specimen Benefits Most From Platinum-Based Neoadjuvant Chemotherapy"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8799-812X","authenticated-orcid":false,"given":"Ziwei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidie","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhensheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxiong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2023.10.014_bib0001","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0002","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.10.014_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9061962","article-title":"Survival outcomes of patients with pathologically proven positive lymph nodes at time of radical cystectomy with or without neoadjuvant chemotherapy","volume":"9","author":"Ploussard","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.clgc.2023.10.014_bib0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.canep.2018.11.007","article-title":"Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis","volume":"58","author":"Mazzone","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0005","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0006","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.euo.2023.03.008","article-title":"Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314","volume":"6","author":"Lu","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0007","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.eururo.2022.07.023","article-title":"Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer","volume":"83","author":"Gil-Jimenez","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0008","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","article-title":"Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes","volume":"81","author":"Sj\u00f6dahl","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23147898","article-title":"Prediction of response to cisplatin-based neoadjuvant chemotherapy of muscle-invasive bladder cancer patients by molecular subtyping including KRT and FGFR target gene assessment","volume":"23","author":"Ecke","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clgc.2023.10.014_bib0010","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1038\/s41467-021-24837-8","article-title":"Reconciling differences in impact of molecular subtyping on response to cisplatin-based chemotherapy","volume":"12","author":"Roumiguie","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.clgc.2023.10.014_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100416","article-title":"Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer","volume":"7","author":"Beije","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.clgc.2023.10.014_bib0012","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/JU.0000000000002261","article-title":"Patients with muscle-invasive bladder cancer with nonluminal subtype derive greatest benefit from platinum based neoadjuvant chemotherapy","volume":"207","author":"Lotan","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/CCI.20.00104","article-title":"College of American Pathologists Cancer Protocols: from optimizing cancer patient care to facilitating interoperable reporting and downstream data use","volume":"5","author":"Torous","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.clgc.2023.10.014_bib0014","doi-asserted-by":"crossref","first-page":"e89259","DOI":"10.1371\/journal.pone.0089259","article-title":"Prognostic significance of lymphovascular invasion in radical cystectomy on patients with bladder cancer: a systematic review and meta-analysis","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2023.10.014_bib0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000499247","article-title":"Preoperative clinical predictors of lymphovascular invasion of bladder tumors at transurethral resection pathology","volume":"14","author":"Yoneda","year":"2020","journal-title":"Curr Urol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.juro.2013.07.061","article-title":"Refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"191","author":"Culp","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0017","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/BLC-160062","article-title":"Utility of clinical risk stratification in the selection of muscle-invasive bladder cancer patients for neoadjuvant chemotherapy: a retrospective cohort study","volume":"3","author":"von Rundstedt","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.clgc.2023.10.014_bib0018","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1158\/1078-0432.CCR-20-0401","article-title":"Noninvasive detection of urothelial carcinoma by cost-effective low-coverage whole-genome sequencing from urine-exfoliated cell DNA","volume":"26","author":"Zeng","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2023.10.014_bib0019","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.1172\/JCI139597","article-title":"Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clgc.2023.10.014_bib0020","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.urolonc.2019.04.010","article-title":"Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival","volume":"37","author":"Kollberg","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0021","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1002\/cncr.32169","article-title":"Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer","volume":"125","author":"Martini","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2023.10.014_bib0022","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0023","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0024","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0025","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/1078-0432.CCR-18-1656","article-title":"Long noncoding RNA LBCS inhibits self-renewal and chemoresistance of bladder cancer stem cells through epigenetic silencing of SOX2","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2023.10.014_bib0026","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1158\/0008-5472.CAN-22-2233","article-title":"NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer","volume":"83","author":"Xie","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2023.10.014_bib0027","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eururo.2017.05.016","article-title":"Oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy: a pathologic stage-matched analysis","volume":"72","author":"Bhindi","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0028","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MOU.0000000000000641","article-title":"Clinical implications of molecular subtyping in bladder cancer","volume":"29","author":"Satyal","year":"2019","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0029","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/21681805.2018.1439527","article-title":"Choline-phosphate cytidylyltransferase-\u03b1 as a possible predictor of survival and response to cisplatin neoadjuvant chemotherapy in urothelial cancer of the bladder","volume":"52","author":"Hemdan","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.clgc.2023.10.014_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061742","article-title":"Refining the characterization and outcome of pathological complete responders after neoadjuvant chemotherapy for muscle-invasive bladder cancer: lessons from the randomized phase III VESPER (GETUG-AFU V05) trial","volume":"15","author":"Culine","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2023.10.014_bib0031","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13000-021-01171-7","article-title":"Tumor cell invasion in blood vessels assessed by immunohistochemistry is related to decreased survival in patients with bladder cancer treated with radical cystectomy","volume":"16","author":"Carlsen","year":"2021","journal-title":"Diagn Pathol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323002343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323002343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:30:39Z","timestamp":1793176239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323002343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1558767323002343"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.10.014","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients With Muscle-Invasive Bladder Cancer With Lymphovascular Invasion in Transurethral Resection Specimen Benefits Most From Platinum-Based Neoadjuvant Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}